Quantcast
Last updated on April 19, 2014 at 17:21 EDT

Latest cancer therapy Stories

2009-10-16 16:31:00

BRIDGEWATER, N.J., Oct. 16 /PRNewswire-FirstCall/ -- Sanofi-aventis U.S. announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Elitek® (rasburicase) to be used for the initial management of plasma uric acid (PUA) levels in adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis syndrome (TLS) and subsequent elevations of plasma uric acid....

2009-10-01 07:00:00

NEW YORK, Oct. 1 /PRNewswire/ -- Released in time for National Breast Cancer Awareness Month, the new documentary Rethinking Cancer presents a compelling look into the therapeutic and psychological journeys of five men and women who chose to use non-toxic, biological therapies to overcome serious illness. Four of the patients featured had been diagnosed with cancers, including breast, lymphatic and bone; and two of these were designated "terminal." Disease-free from 15 - 37 years, they are...

2009-09-24 06:30:00

CALGARY, Sept. 24 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that the Cancer Therapy Research Center at the University of Texas Health Science Center (CTRC) has started patient enrolment in a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with metastatic melanoma. The Principal Investigator is Dr. Devalingam Mahalingam, M.D., Ph.D., MRCP(UK),...

2009-07-30 07:00:00

WILMINGTON, Del., July 30 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced the company has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) and a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMEA) for an investigational drug, vandetanib 100 mg for use in combination with chemotherapy for the treatment of advanced non-small cell lung cancer in patients previously treated with one prior anti-cancer therapy. The...

2009-06-18 14:53:29

Chemists at the University of California-Santa Cruz say they've developed novel compounds that show promise for photodynamic cancer therapy. The compounds, called dye-sensitized ruthenium nitrosyls, are absorbed by cancer cells and respond to specific wavelengths of light by releasing nitric oxide, which triggers the cancer cells' death, the researchers said. For cancer treatment, you want localized delivery of a very high concentration of nitric oxide, said Professor Pradip Mascharak. We've...

2009-03-31 04:00:00

DOYLESTOWN, Pennsylvania and OXFORD, England, March 31 /PRNewswire/ -- EUSA Pharma Inc ('EUSA'), a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care, announced today the successful completion of its European launch of CAPHOSOL(R) for the prevention and treatment of oral mucositis associated with cancer therapy, as an adjunct to standard oral care. CAPHOSOL is also indicated for hyposalivation and xerostomia (dryness of the mouth or throat)...

2009-02-17 06:50:00

LONDON, Feb. 17 /PRNewswire/ -- Cancer may well surpass cardiovascular diseases as the primary case of death in Europe by 2012. To prevent this from happening, cancer therapeutics have to shift in focus from the treatment of symptoms to offering a total cure, despite the complex, multifactorial nature of cancer indications. (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO) "As cancer spreads rapidly through Europe, therapy developers are looking to improve the cancer...

2008-10-14 09:00:45

SALT LAKE CITY, Oct. 14, 2008 (GLOBE NEWSWIRE) -- BSD Medical Corporation (Nasdaq:BSDM) announced today that a member of its Board of Directors, Dr. Michael Nobel, was the keynote speaker at the Japanese Cancer Symposium recently concluded at the Shizuoka Cancer Center in Shizuoka, Japan. The symposium addressed the theme, "Fulfilling the Promise of Personalized Medicine in Cancer Therapy: Development of the Medical Engineering Platform." The symposium was sponsored by the Frontier...

2008-09-15 12:00:35

SCOTTSDALE, Ariz., Sept. 15 /PRNewswire/ -- Carefx Corporation today announced that the nationally recognized Cancer Therapy & Research Center (CTRC) at the University of Texas Health Science Center at San Antonio, Texas, has gone live after a 90-day implementation with Fusion from Carefx(R), an interoperability platform that aligns patient data across multiple applications to provide a complete view of patient health history. One of only three National Cancer Institute-designated...

2008-06-25 09:02:22

By Mankoff, David A Link, Jeanne M; Linden, Hannah M; Sundararajan, Lavanya; Krohn, Kenneth A Tumor receptors play an important role in carcinogenesis and tumor growth and have been some of the earliest targets for tumor- specific therapy, for example, the estrogen receptor in breast cancer. Knowledge of receptor expression is key for therapy directed at tumor receptors and traditionally has been obtained by assay of biopsy material. Tumor receptor imaging offers complementary information...